NCT04218188 is a clinical trial in Clinical Decision-Making, sponsored by National Taiwan University Hospital.

Who is sponsoring NCT04218188?

NCT04218188 is sponsored by National Taiwan University Hospital.

What condition does NCT04218188 study?

NCT04218188 studies Clinical Decision-Making, Early Detection of Cancer.

Is NCT04218188 still recruiting?

NCT04218188 is currently status unknown. Last updated 14 January 2020.

Last reviewed 2020-01-14 · How we verify

NCT04218188

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Evaluation of the Cell Detachment Ratio on pH-responsive Chitosan as a Prognostic Factor in Lung Cancer

Status unknown Last updated 14 January 2020

What this trial tests

trial in Clinical Decision-Making in 120 participants. Status unknown.

Timeline

5 January 2020

Primary endpoint
17 November 2020

1 December 2022

Quick facts

Lead sponsor	National Taiwan University Hospital
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	120
Start date	5 January 2020
Primary completion	17 November 2020
Estimated completion	1 December 2022
Sites	1 location across Taiwan

Conditions studied

Clinical Decision-Making — all drugs for Clinical Decision-Making →
Early Detection of Cancer — all drugs for Early Detection of Cancer →

Sponsor

National Taiwan University Hospital

Who can join

Adults 20 to 70, any sex, with Clinical Decision-Making or Early Detection of Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Biomaterial-based cell culture models have been gaining increasing attention as potential therapeutic strategies. The purpose of this project is to evaluate whether the cell detachment ratio on pH-responsive chitosan could be correlated with the overall survival in lung cancer patients. Through controllable cell-material interaction, this project has the intention to develop an alternative tool for both early diagnosis and accurate prognosis in cancer therapeutics.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

Tumor microenvironment penetrating chitosan nanoparticles for elimination of cancer relapse and minimal residual disease.
Mahmudi H, Adili-Aghdam MA, Shahpouri M, Jaymand M, et al · · 2022 · cited 22× · PMID 36531004 · DOI 10.3389/fonc.2022.1054029
Biomedical applications of stimuli-responsive nanomaterials.
Chen X, Wu D, Chen Z. · · 2024 · cited 14× · PMID 39036340 · DOI 10.1002/mco2.643
Advances in Chitosan-Based Smart Hydrogels for Colorectal Cancer Treatment.
Piotrowska U, Orzechowska K. · · 2024 · cited 13× · PMID 39458901 · DOI 10.3390/ph17101260
Chitosan-Based Drug Delivery Systems for Targeted Chemotherapy in Colorectal Cancer: A Scoping Review.
Piotrowska U, Szatko J, Nowakowska A, Klimaszewska E, et al · · 2025 · PMID 41440901 · DOI 10.3390/md23120467

Verify or expand the search:

Other National Taiwan University Hospital trials

Trials by the same sponsor.

NCT06936917 — Timing for Computed Tomography and Post-Resuscitation Care on Short-Term Outcomes in Out-of-Hospital Cardiac Arrest · not yet recruiting
NCT05396222 — A Prospective Study of the Safety and Efficacy of 3D-printed Non-rigid Biomimetic Implant in Cervical and Thoracolumbar · NA · not yet recruiting
NCT07532356 — Integrating Tumor Genomics and Urinary Exosomal Proteomics to Establish a Multi-Layer Biomarker Framework for Early Risk · not yet recruiting
NCT07317310 — The NTU JO-SMART Study · NA · not yet recruiting
NCT07382024 — Tirzepatide to Reduce rEcurrence And Burden After Ablation of Atrial Fibrillation · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04218188 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by National Taiwan University Hospital
Last refreshed: 14 January 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04218188.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing